<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>32 Thrombosis and thrombophilia</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-31-disorders-of-coagulation-II-acquired.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 80%;"></div>
                        </div>
                       <span class="progress-text">Lecture 32 of 40</span>
                    </div>
                    <a href="haematology-33-anticoagulation.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">32 Thrombosis and thrombophilia</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="thrombosis" class="content-section" aria-labelledby="section-heading-1">
                    <h2 id="section-heading-1" class="section-heading">
                        <span class="heading-text">Thrombosis</span>
                    </h2>
                    <div class="content-card">
                        <p>Thrombosis is the pathological process whereby platelets and fibrin interact with the vessel wall to form a haemostatic plug to cause vascular obstruction. It may be arterial, causing ischaemia, or venous leading to stasis (Fig.32.1). The thrombus may be subsequently lysed by fibrinolysis, organize, recanalize or embolize. Thrombosis underlies ischaemic heart, cerebrovascular and peripheral vascular disease; venous occlusion and pulmonary embolism; and it plays an important part in pre-eclampsia.</p>
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-089-1.jpg" alt="Fig. 32.1 Venogram showing filling defects in a deep vein, indicating a thrombus, in a patient with polycythaemia." class="content-image">
                            <figcaption>Fig. 32.1 Thrombosis: venogram showing filling defects due to a deep vein thrombus in a patient with polycythaemia.</figcaption>
                        </figure>

                        <h3 class="subsection-heading">Arterial thrombosis (Table 32.1)</h3>
                        <p>This occurs in relation to damaged endothelium, e.g. atherosclerotic plaques. Exposed collagen and released tissue factor cause platelet aggregation and fibrin formation.</p>

                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 32.1 Risk factors for arterial thrombosis.</caption>
                                 <tbody>
                                     <tr><td>Hypertension</td></tr>
                                     <tr><td>Smoking</td></tr>
                                     <tr><td>Diabetes*</td></tr>
                                     <tr><td>Hyperlipidaemia*</td></tr>
                                     <tr><td>↑ Homocysteine*</td></tr>
                                     <tr><td>Polycythaemia/thrombocythaemia</td></tr>
                                     <tr><td>↑ Factor VIII</td></tr>
                                     <tr><td>↑ Fibrinogen</td></tr>
                                     <tr><td>Lupus anticoagulant</td></tr>
                                 </tbody>
                                 <tfoot>
                                    <tr><td style="font-size: 0.9em; padding-top: 1em;">*May be related to an inherited abnormality.</td></tr>
                                 </tfoot>
                             </table>
                        </div>

                        <h3 class="subsection-heading">Venous thrombosis (Table 32.2)</h3>
                        <p>Factors affecting blood flow (e.g. stasis, obesity), alterations in blood constituents and damage to vascular endothelium (e.g. caused by sepsis, surgery or indwelling catheters) are important risk factors.</p>
                        
                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 32.2 Risk factors for venous thrombosis.</caption>
                                 <tbody>
                                     <tr>
                                         <td><strong>Conditions causing stasis</strong></td>
                                         <td>Cardiac failure, oedema, nephrotic syndrome<br>Postoperative<br>Immobility and bed rest<br>Trauma<br>Pelvic obstruction</td>
                                     </tr>
                                     <tr>
                                         <td><strong>Altered blood constituents</strong></td>
                                         <td><em>Coagulation factors</em><br><strong>Hereditary</strong><br>Factor V Leiden<br>Protein C deficiency<br>Protein S deficiency<br>Antithrombin deficiency<br>Prothrombin mutation<br><strong>Acquired</strong><br>Oestrogen therapy, contraceptive pill<br>Malignancy<br>Pregnancy and puerperium<br>Lupus anticoagulant<br>Raised plasma homocysteine (may also be inherited)<br><em>Blood cells</em><br>Polycythaemia<br>Thrombocythaemia</td>
                                     </tr>
                                 </tbody>
                             </table>
                        </div>
                    </div>
                </section>

                <section id="thrombophilia" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Thrombophilia</span>
                    </h2>
                    <div class="content-card">
                        <p>Thrombophilia is a congenital or acquired predisposition to thrombosis. It should be suspected and screened for in patients who are young, have a positive family history, have a thrombosis in an unusual site and in females with recurrent fetal loss.</p>
                        
                        <h3 class="subsection-heading">Inherited thrombophilia</h3>
                        <p>This has been increasingly recognized recently (Tables 32.1 and 32.2; Fig. 32.2). Presentation may be during early childhood or in adulthood, e.g. at commencement of oral contraceptives or during pregnancy/puerperium. Inheritance of a variant form of factor V (factor V Leiden) is the most common (up to 5% of the population). Activated factor V Leiden is relatively resistant to inactivation by protein C. The risk of thrombosis is increased 5- to 10-fold in heterozygotes, and 50- to 100-fold in homozygotes. Rarer causes include protein C, protein S or antithrombin deficiency or functional abnormality, defective fibrinolysis (e.g. TPAI deficiency, see Chapter 28), mutant prothrombin and homocystinuria. The combination of two abnormalities often underlies severe cases.</p>
                        
                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-089-2.jpg" alt="Fig. 32.2 Diagram of the protein C pathway, showing how thrombin bound to thrombomodulin activates protein C, which then, with protein S, inactivates factors Va and VIIIa. Factor V Leiden is resistant to this inactivation." class="content-image">
                            <figcaption>Fig.32.2 The protein C pathway. Thrombin bound to thrombomodulin (TM) on intact endothelium activates protein C to activated protein C (APC). This combines with protein S (PS) and inactivates Va and VIIIa. Factor V Leiden is resistant to APC.</figcaption>
                        </figure>

                        <h3 class="subsection-heading">Acquired thrombophilia</h3>
                        <p>Acquired hypercoagulable states are listed in Tables 32.2. Pathogenesis, e.g. in pregnancy, oral contraceptive pill therapy and malignancy, is multifactorial and relates to elevated levels of procoagulant factors, depressed levels of inhibitor proteins and physical factors (e.g. stasis, surgery).</p>
                    </div>
                </section>

                <section id="lupus-anticoagulant" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Lupus anticoagulant syndrome</span>
                    </h2>
                    <div class="content-card">
                        <p>Despite its name, this syndrome usually presents with arterial or venous thrombosis or recurrent miscarriages. It may be associated with systemic lupus erythematosus or other connective tissue disorders, with malignancy or infections or be idiopathic. Patients may show a spectrum of antibodies which interfere with phospholipid-dependent coagulation tests in vitro and/or react with cardiolipin. The APTT is prolonged and not corrected by a 50:50 mix of normal plasma in patient plasma. Anticoagulant therapy is needed for patients with thrombosis.</p>
                    </div>
                </section>

                <section id="antiplatelet-therapy" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Antiplatelet therapy</span>
                    </h2>
                    <div class="content-card">
                        <p>The use of heparin and warfarin is discussed in Chapter 33. Antiplatelet drugs (see Chapter 2, Fig. 2.8) and fibrinolytic drugs are discussed here.</p>
                        <ul>
                            <li>Aspirin (75 mg daily and 300 mg post myocardial infarction) is most widely used. It inhibits platelet function by inhibiting cyclo-oxygenase thus reducing thromboxane A<sub>2</sub> production.</li>
                            <li>Others: ticlopidine and monoclonal antibodies directed to platelet glycoproteins (e.g. GP IIb/IIIa) are used, for example, post angiography.</li>
                        </ul>
                        <h3 class="subsection-heading">Indications</h3>
                        <p>Prevention of thrombosis in patients with:</p>
                        <ul>
                            <li>previous myocardial infarction, transient ischaemic attacks and stroke or high risk of first myocardial infarct in males;</li>
                            <li>thrombocytosis, e.g. myeloproliferative disorders, post splenectomy;</li>
                            <li>prosthetic valves and post coronary artery surgery or angioplasty;</li>
                            <li>pre-eclampsia; and</li>
                            <li>severe peripheral vascular disease.</li>
                        </ul>
                    </div>
                </section>

                <section id="fibrinolytic-therapy" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Fibrinolytic therapy</span>
                    </h2>
                    <div class="content-card">
                        <p>This is used to enhance conversion of plasminogen to plasmin (see Chapter 28, Fig.28.4), which degrades fibrin. They must be used within 5-7 days for venous thrombi and 5-7 h for arterial thrombi.</p>
                        <ul>
                            <li>Streptokinase directly activates plasminogen. Most individuals have antistreptococcal antibodies; a loading dose is therefore required and treatment becomes ineffective after 4-10 days.</li>
                            <li>Urokinase has a similar action but may be used if there are high levels of antistreptococcal antibodies. Single chain urokinase-type plasminogen activator (SCU-PA) has also been developed.</li>
                            <li>Acylated plasminogen streptokinase activator complex (APSAC) activates streptokinase bound to plasminogen.</li>
                            <li>Recombinant tissue plasminogen activation (TPA) causes activation of fibrin-bound plasminogen only, and is associated with less systemic activation of fibrinolysis.</li>
                        </ul>
                        <h3 class="subsection-heading">Indications</h3>
                        <ul>
                            <li>Acute myocardial infarction: streptokinase is usually given with 300 mg aspirin and heparin intravenously.</li>
                            <li>Treatment of arterial and venous thrombosis, e.g. pulmonary embolism, peripheral arterial or venous thrombosis.</li>
                        </ul>
                        <h3 class="subsection-heading">Contraindications</h3>
                        <ul>
                            <li>Patients with active gastrointestinal bleeding, aortic dissection. head injury or recent (&lt;2 months) neurosurgery, and bleeding diathesis.</li>
                        </ul>
                        <h3 class="subsection-heading">Side effects</h3>
                        <ul>
                            <li>Bleeding, especially in patients taking anticoagulants or antiplatelet drugs.</li>
                            <li>Anaphylactic reactions may occur with streptokinase.</li>
                        </ul>
                    </div>
                </section>
                
            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-31-disorders-of-coagulation-II-acquired.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 80%;"></div>
                        </div>
                       <span class="progress-text">Lecture 32 of 40</span>
                    </div>
                    <a href="haematology-33-anticoagulation.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>